NanoSomiX
NanoSomiX is a pioneering company focused on developing non-invasive blood-based testing technologies for neurological disorders using Brain Derived Exosomes (BDE). Their innovative assays aim to improve research and clinical applications by enabling biomarker exploration in neurologic conditions such as Alzheimer’s disease, stroke, traumatic brain injury, and neurodegenerative disorders. With proprietary exosome isolation and analysis technologies covered by multiple patents, NanoSomiX collaborates with academic and industry partners to advance biomarker discovery, diagnosis, and monitoring of brain health through simple blood tests.
Industries
Nr. of Employees
small (1-50)
NanoSomiX
Aliso Viejo, California, United States, North America
Patents
Quantification of subpopulations of exosomes and diagnosis of neurogenerative disorders
US-11852635-B2
View DetailsBiomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders
US-11619637-B2
View DetailsBiomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
US-10203342-B2
View DetailsBiomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders
US-9958460-B2
View Details
Quantification of subpopulations of exosomes and diagnosis of neurogenerative disorders
US-11852635-B2
View DetailsBiomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders
US-11619637-B2
View DetailsBiomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
US-10203342-B2
View DetailsBiomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders
US-9958460-B2
View DetailsProducts
Exosome-based blood assay for phosphorylated tau (p-tau)
A blood-based assay that measures p-tau within neuron-derived exosomes as a biomarker associated with Alzheimer’s disease, designed for research and clinical-trial enrichment applications.
Brain Derived
A unique suite of assays that can measure biomarkers from Brain Derived Exosomes (BDE) and Neuron Derived Exosomes (NDE) using a simple blood draw to support research in basic and clinical applications.
Brain Derived Exosome Assay Technology
Proprietary blood-based assay technology utilizing brain-derived exosomes (BDE) to assess brain biomarkers and provide information on the status of brain tissue for research and clinical applications.
NanoSomiX Technology Platform
A proprietary technology platform for isolating plasma-borne brain-derived exosomes (BDE) and assessing associated clinically relevant biomarkers using a three-dimensional approach including expanded cell sources, separate protein analysis, and sandwich immunoassays.
Exosome-based blood assay for phosphorylated tau (p-tau)
A blood-based assay that measures p-tau within neuron-derived exosomes as a biomarker associated with Alzheimer’s disease, designed for research and clinical-trial enrichment applications.
Brain Derived
A unique suite of assays that can measure biomarkers from Brain Derived Exosomes (BDE) and Neuron Derived Exosomes (NDE) using a simple blood draw to support research in basic and clinical applications.
Brain Derived Exosome Assay Technology
Proprietary blood-based assay technology utilizing brain-derived exosomes (BDE) to assess brain biomarkers and provide information on the status of brain tissue for research and clinical applications.
NanoSomiX Technology Platform
A proprietary technology platform for isolating plasma-borne brain-derived exosomes (BDE) and assessing associated clinically relevant biomarkers using a three-dimensional approach including expanded cell sources, separate protein analysis, and sandwich immunoassays.
Services
Collaborative and fee-for-service research to confirm detection of brain-derived exosome biomarkers, design study protocols, develop assays, and test clinical or preclinical samples for academic and industry partners.
Laboratory testing services performed in a CLIA-regulated laboratory for blood-based exosome assays, with the ability to transition validated markers to Laboratory Developed Tests.
Collaborative and fee-for-service research to confirm detection of brain-derived exosome biomarkers, design study protocols, develop assays, and test clinical or preclinical samples for academic and industry partners.
Laboratory testing services performed in a CLIA-regulated laboratory for blood-based exosome assays, with the ability to transition validated markers to Laboratory Developed Tests.
Expertise Areas
- Exosome isolation and characterization
- Blood-based neurological biomarker assay development
- Biomarker discovery and validation for neurologic disorders
- Clinical sample testing and LDT development (CLIA)
Key Technologies
- Immunoaffinity capture of extracellular vesicles
- Two-antibody sandwich immunoassays for vesicle quantification
- ELISA-based protein detection from vesicle preparations
- Surface vs cargo (core) exosome protein analysis
News & Updates
A study assessing neuron- and astrocyte-derived exosomes following intracerebral hemorrhage, presented at the Neurocritical Care Society Annual Meeting.
A series of studies in collaboration with Southern California Fights to monitor BDE biomarkers in boxers and MMA fighters for concussion research.
Research demonstrating elevation of ADE levels in the first month after ischemic stroke, indicating potential for monitoring injury and hemorrhagic transformation.
NanoSomiX patents and technological advancements
Issuance of U.S. Patent No. 11,852,635 B2 covering exosome detection and biomarker diagnosis for neurodegenerative disorders.
Research demonstrating a blood test that detects brain insulin resistance and predicts Alzheimer’s disease up to 10 years before onset.
Research showing elevated plasma astrocyte-derived exosomes in the first month after ischemic stroke, with potential implications for prognosis.
A study assessing neuron- and astrocyte-derived exosomes following intracerebral hemorrhage, presented at the Neurocritical Care Society Annual Meeting.
A series of studies in collaboration with Southern California Fights to monitor BDE biomarkers in boxers and MMA fighters for concussion research.
Research demonstrating elevation of ADE levels in the first month after ischemic stroke, indicating potential for monitoring injury and hemorrhagic transformation.
NanoSomiX patents and technological advancements
Issuance of U.S. Patent No. 11,852,635 B2 covering exosome detection and biomarker diagnosis for neurodegenerative disorders.
Research demonstrating a blood test that detects brain insulin resistance and predicts Alzheimer’s disease up to 10 years before onset.
Research showing elevated plasma astrocyte-derived exosomes in the first month after ischemic stroke, with potential implications for prognosis.